Inflammatory myopathies

Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies

Arthritis Res TherPublished Diagnostic accuracy study

Authors' conclusion

Combination of CD163 and MHC class I muscular expression may be useful in diagnosing IIMs.

Study context

Population
Muscle biopsy tissues from IIM patients meeting 2017 EULAR/ACR criteria and controls with non-inflammatory myopathies or healthy muscle
Comparison
Algorithm combining CD163 and MHC class I muscular expression vs IIM-related histopathologic features for diagnosing IIM
  • IIMn = 129
  • Controln = 73reference
Outcome
Diagnostic ability for IIM of an inflammation-related immunohistochemistry marker-based algorithm
Methodological detailsclassification and regression tree (CART) analysis
  • Classification and regression tree (CART) analysis

Performance

As reported in the abstract

Diagnostic performance for IIM
Test or modelSensitivitySpecificityAccuracy
CD163 + MHC class I algorithm96.1%94.5%95.5%
IIM-related histopathologic features80.6%100.0%87.6%

Sensitivity

CD163 + MHC class I algorithm96.1%
IIM-related histopathologic features80.6%

Specificity

CD163 + MHC class I algorithm94.5%
IIM-related histopathologic features100.0%

Accuracy

CD163 + MHC class I algorithm95.5%
IIM-related histopathologic features87.6%

Further findings

OutcomeIIMControlP value
Muscular CD163 expressionIIM vs Control99.2%20.8%P < 0.001
Muscular MHC class I expressionIIM vs Control87.6%23.1%P < 0.001

Correct IIM diagnosis by the algorithm in patients not meeting 2017 EULAR/ACR criteria but diagnosed with IIM by an expert physician (subgroup)

Algorithm correctly diagnosed IIM
94.1% (16/17)

Original publication

Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies. Arthritis Res Ther. Published 30 July 2024. doi:10.1186/s13075-024-03364-z

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.